Literature DB >> 6775954

Intestinal solubilization, absorption, pharmacokinetics and bioavailability of chenodeoxycholic acid.

M Ponz de Leon, P Loria, N Carulli, G M Murphy, R H Dowling.   

Abstract

Little is known about the physical state, intestinal solubilization, absorption and bioavailability of chenodeoxycholic acid used in the medical treatment of gallstones. Therefore the concentrations of unconjugated chenodeoxycholic acid were measured in the supernatant and precipitate phases of intestinal contents aspirated from stomach, duodenum and jejunum of nine control subjects who took 500 mg chenodeoxycholic acid (4 X 125 mg gelatin-coated capsules) either fasting or together with a standard liquid meal. Chenodeoxycholic acid solubility was markedly influenced by luminal pH but was little affected by endogenous conjugated bile acids when their concentrations were > 1-2 mmol/l. Systemic bioavailability of 250, 500 and 750 doses of chenodeoxycholic acid was measured in five subjects by comparing areas under 4 h serum concentration-time curves after giving the bile acid first as a bolus intraduodenal aqueous infusion of 3H-labelled chenodeoxycholic acid containing either 14C-polyethylene glycol or bromsulphthalein as non-absorbable markers, and then as gelatin-coated capsules by mouth. Absorption was assessed by measuring the ratio of marker: bile acid in intestinal contents aspirated for 2 h from sites 60 and 120 cm distal to the duodenal infusion port and in three subjects quantitative recovery of marker was measured proximal to an occluding intestinal balloon. Absorption of duodenally-infused chenodeoxycholic acid was 96-99% complete and bioavailability was complete with the 250 and 500 mg doses but fell to 81% with the 750 mg dose.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6775954     DOI: 10.1111/j.1365-2362.1980.tb00032.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  7 in total

1.  Famotidine does not affect indocyanine green disposition and serum bile acid levels in healthy subjects.

Authors:  R Testa; A Grasso; F Dagnino; R Ibba; G Varagona; G Celle
Journal:  Br J Clin Pharmacol       Date:  1987-06       Impact factor: 4.335

Review 2.  Ursodeoxycholic acid in the treatment of cholesterol cholelithiasis. Part II.

Authors:  W H Bachrach; A F Hofmann
Journal:  Dig Dis Sci       Date:  1982-09       Impact factor: 3.199

3.  Pilot study of combination treatment for gall stones with medium dose chenodeoxycholic acid and a terpene preparation.

Authors:  W R Ellis; K W Somerville; B H Whitten; G D Bell
Journal:  Br Med J (Clin Res Ed)       Date:  1984-07-21

4.  Improved intestinal absorption of an enteric-coated sodium ursodeoxycholate formulation.

Authors:  A Roda; E Roda; E Marchi; P Simoni; C Cerrè; A Pistillo; C Polimeni
Journal:  Pharm Res       Date:  1994-05       Impact factor: 4.200

5.  Gallstone dissolution rate during chenic acid therapy. Effect of bedtime administration plus low cholesterol diet.

Authors:  R M Kupfer; D P Maudgal; T C Northfield
Journal:  Dig Dis Sci       Date:  1982-11       Impact factor: 3.199

Review 6.  Chenodeoxycholic acid: a review of its pharmacological properties and therapeutic use.

Authors:  J H Iser; A Sali
Journal:  Drugs       Date:  1981-02       Impact factor: 9.546

7.  Intestinal absorption of unconjugated dihydroxy bile acids: non-mediation by the carrier system involved in long chain fatty acid absorption.

Authors:  W Stremmel; A F Hofmann
Journal:  Lipids       Date:  1990-01       Impact factor: 1.880

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.